Sandoz wants Novo's sole US Prandin patent ruled invalid in a long running case
This article was originally published in Scrip
Executive Summary
Novartis's generics unit Sandoz filed a suit 17 August in a Michigan federal court seeking to have Novo Nordisk's sole remaining US patent protecting the diabetes drug Prandin declared – for a second time - invalid and unenforceable.